Sugi Predict

Sugi Predict / Compounds / SCHEMBL3880729

SCHEMBL3880729

SCHEMBL3880729

Cc1csc(N)c1S(N)(=O)=O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ CA2 P00918 12/20 0.33
▸ CA1 P00915 8/20 0.33
▸ CA7 P43166 8/20 0.33
▸ CA4 P22748 4/20 0.33
▸ CA12 O43570 4/20 0.32
▸ CA6 P23280 2/20 0.32
▸ CA9 Q16790 2/20 0.32
▸ CA3 P07451 1/20 0.32
▸ CA5A P35218 1/20 0.32
▸ CA5B Q9Y2D0 1/20 0.32
▸ CA13 Q8N1Q1 4/20 0.32
▸ MAPT P10636 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6150867 0.80 CA2 (0.33) LMNAALDH1A1KDM4ECA2CA1
SCHEMBL10808265 0.77 CA2 (0.35) LMNAALDH1A1CA2CA1CA7
SCHEMBL12616632 0.75 CA2 (0.35) ALDH1A1CA2CA1CA7CA4
SCHEMBL336386 0.74 — —
SCHEMBL1523787 0.72 CA2 (0.46) LMNAALDH1A1KDM4ECA2CA1
SCHEMBL7025892 0.72 MAPT (0.48) LMNAKDM4EMAPT
SCHEMBL7826185 0.72 — —
SCHEMBL10750547 0.72 L3MBTL1 (0.46) LMNAALDH1A1KDM4ECA2MAPT
SCHEMBL4000892 0.71 CA12 (0.38) CA2CA1CA12CA9
SCHEMBL1801319 0.71 CYP2A6 (0.33) CA2CA1CA7CA4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476668-B2 Thiadiazine derivatives and use thereof as positive AMPA receptor modulators LES LABORATOIRES SERVIER (FR) 2009-01-13 — — US disclosed
US-20070004709-A1 Thiadiazine derivatives and use thereof as positive ampa receptor modulators THE UNIVERSITE DE LIEGE (BE) 2007-01-04 — — US disclosed
EP-1620441-A1 THIADIAZINE DERIVATIVES AND USE THEREOF AS POSITIVE AMPA RECEPTOR MODULATORS LES LABORATOIRES SERVIER (FR) 2006-02-01 — — EP disclosed
WO-2004099217-A1 THIADIAZINE DERIVATIVES AND USE THEREOF AS POSITIVE AMPA RECEPTOR MODULATORS LES LABORATOIRES SERVIER (FR) 2004-11-18 — — WO disclosed
US-6225310-B1 Fused 1,2,4-thiadiazine derivatives, their preparation and use NOVO NORDISK A/S (DK) 2001-05-01 — — US disclosed
CN-1264384-A Fused 1,2,4-thiadiazine derivatives, their preparation method and use NOVO NORDISK AS (DK) 2000-08-23 — — CN disclosed
EP-1000066-A1 FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-05-17 — — EP disclosed
WO-1999003861-A1 FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-01-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004709-A1 Thiadiazine derivatives and use thereof as positive ampa receptor modulators GRM1, GRM3, GABRA1 LMNA 4589/4885ALDH1A1 1027/4885KDM4E 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.